Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.
Rapid improvements in the detection and tracking of early-stage tumor progression aim to guide decisions regarding cancer treatments as well as predict metastatic recurrence in patients following surgery. Mathematical models may have the potential to further assist in estimating metastatic risk, particularly when paired with in vivo tumor data that faithfully represent all stages of disease progression. Herein, we describe mathematical analysis that uses data from mouse models of spontaneous metastasis developing after surgical removal of orthotopically implanted primary tumors. Both presurgical (primary tumor) growth and postsurgical (metastatic) growth were quantified using bioluminescence and were then used to generate a mathematical formalism based on general laws of the disease (i.e., dissemination and growth). The model was able to fit and predict pre/postsurgical data at the level of the individual as well as the population. Our approach also enabled retrospective analysis of clinical data describing the probability of metastatic relapse as a function of primary tumor size. In these data-based models, interindividual variability was quantified by a key parameter of intrinsic metastatic potential. Critically, our analysis identified a highly nonlinear relationship between primary tumor size and postsurgical survival, suggesting possible threshold limits for the utility of tumor size as a predictor of metastatic recurrence. These findings represent a novel use of clinically relevant models to assess the impact of surgery on metastatic potential and may guide optimal timing of treatments in neoadjuvant (presurgical) and adjuvant (postsurgical) settings to maximize patient benefit.
Inria Bordeaux Sud-Ouest, Team MONC, Institut de Mathematiques de Bordeaux, Bordeaux, France. sebastien.benzekry@inria.fr.
Sebastien
S
Benzekry
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Amanda
A
Tracz
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Michalis
M
Mastri
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Ryan
R
Corbelli
SMARTc Pharmacokinetics Unit, Inserm S 911 CRO2, Aix Marseille University, Marseille, France.
Dominique
D
Barbolosi
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
John M L
JM
Ebos
D000818:Animals; D045744:Cell Line, Tumor; D003198:Computer Simulation; D005260:Female; D064593:Heterografts; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000601:surgery; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000473:pathology* / Q000601:surgery*